MD

2000: Degree in Medicine and Surgery, University of Bologna, final grade: 110/110, with honors.
 

2004: Medical Oncology Fellowship, Bologna, with grade 70/70, with honors.
2006: Master in Breast Cancer, University of Turin and Bologna.
From 2014: Oncology, Haematology, Pathology PhD.

• 2004-2005: AIRC Research Grant, Ospedale Bellaria Bologna;
• 2005- 2010: Attending Staff Physician, Research Contract, Department of Chemotherapy for rare musculoskeletal tumors, Rizzoli Orthopaedic Institute;
• From 2010: Prometeo Laboratory, Clinical and Experimental Research Contract, Department of Chemotherapy for rare musculoskeletal tumors, Rizzoli Orthopaedic Institute.

Mother language: Italian.
Other languages: English (excellent), French (fluent).

Office (Word, Excel, PowerPoint), SPSS.

Elective Course of Medical tratment of Bone Metastases, Faculty of Medicine.

Research Grants:

• 2004-2005: AIRC Research  Grant, Ospedale Bellaria Bologna (FIRC: Italian Foundation for Cancer Research): Mechanisms of endocrine therapy resistance: estrogen receptor and epidermal growth factor receptor in breast cancer;
• 2013: 3-year Young Investigators Translational  Research Grant “Alessandro Liberati”: Assessment of MGMT promoter methylation and clinical benefit from temozolomide-based therapy in Ewing sarcoma patients.

Clinical Research Experience:

• 2001: Visiting Research Fellow,  Rockefeller University, New Yor;
• 2001: Clinical Observer, Memorial Sloan-Kettering Cancer Center, New York;
• 2003: Dompè Course, “Anemia in cancer patients” Karolinska Institute, Stockholm;
• 2006: ESMO Translational Research Unit Visit, Institute Gustave Roussy, Paris;
• 2007: 1° ESH/EBMT Course: “Blood and marrow  transplantation Children”, Genova

Scientific and Medical Societies:

• 2003-present: American Society of Clinical Oncology (ASCO);
• 2004-present:  Italian Society of Medical Oncology (AIOM);
• 2005-present: European Society for Medical oncology (ESMO).

Awards:

• 2002:  “Evaristo Stefanelli” Award,  Università di Bologna;
• 2003: “Lancet Travel Grant”, to attend the 39° ASCO Annual Meeting;
• 2004: FIRC-AIRC Grant;
• 2005, 2006, 2008, 2009: ASCO Foundation Abstract Merit Award”;
• 2005: Special correspondent Project, AMGEN, to attend the 41° ASCO Annual Meeting;
• 2006: “ESMO Translational Research Unit Visit Award”, Istituto Gustave Roussy;
• 2006: AIOM Best Abstract Award";
• 2010: ESMO Congress Travel Grant;
• 2014: ESMO Congress Travel Grant, Madrid, Spain.

Pubblications. Author of several papers (>45) on international scientific journals and author of 3 book chapters.

Clinical Protocol Experience (Phase II, role: sub-I):

• Pemetrexed (Alimta, ®Lilly) in metastatic osteosarcoma
• STI571 (Glivec, ®Novartis) in chondrosarcoma
• ET 743 (Yondelis, Pharmamar) neoadjuvant in sarcomas
• ET 743 (Yondelis, Pharmamar) metastatic sarcomas
• CP-751,871 (Pfizer) in metastatic Ewing sarcomas
• Denosumab (Amgen) in metastatic/unresectable GCT
• Lapatinib (Tyverb®) in advanced chordomas
• R1507 (Roche) in metastatic Ewing  sarcomas
• Deforolimus (Ariad), in responding sarcomas
• IPI 926 (Infinity), in metastastic chondrosarcomas
• Zalypsis® (PM00104), in metastastic  Ewing sarcoma
• Sorafenib/Everolimus in metastatic osteosarcoma
• NGR-hTNF in metastastatic soft tissue sarcoma
• ISG STS 10.01: targeted vs. untargeted STS adjuvant
• Morab-004 (Morphotek) in metastatic sarcoma

Musculoskeletal Oncology, Bone and Soft Tissue tumors Clinical Research Protocols.